The development, safety and efficacy of pacritinib for the treatment of myelofibrosis

Tania Jain, Ruben Mesa

Research output: Contribution to journalArticle

Abstract

Introduction: Dysregulation of janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has been described in myelofibrosis (MF). Currently, there is an unmet need for agents that have the benefit of JAK inhibition, yet also are safe and effective in patients with thrombocytopenia. Areas covered: We discuss the various preclinical and clinical studies describing pacritinib, a selective JAK2/FLT3 inhibitor. So far, it has shown promising results, without significant thrombocytopenia. A PubMed search, using keywords ‘pacritinib’, ‘SB 1518’ and ‘myelofibrosis’ was conducted. Published abstracts from recent national and international meetings were also reviewed for unpublished data. Expert commentary: Currently, pacritinib is on hold by Food and Drugs Administration. It would be imperative to understand if there is a treatment related toxicity that would limit its use. If a safe path is found for this agent, it could have a significant benefit in various settings, based on the data so far.

Original languageEnglish (US)
Pages (from-to)1101-1108
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume16
Issue number11
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Bridged-Ring Compounds
fms-Like Tyrosine Kinase 3
Janus Kinase 2
Pyrimidines
Primary Myelofibrosis
Drug Design
Protein Kinase Inhibitors
Thrombocytopenia
Anemia
Janus Kinases
Safety
United States Food and Drug Administration
Transducers
PubMed
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene

Keywords

  • Anemia
  • JAK2 inhibitor
  • Myelofibrosis
  • Pacritinib
  • Thrombocytopenia

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. / Jain, Tania; Mesa, Ruben.

In: Expert Review of Anticancer Therapy, Vol. 16, No. 11, 01.11.2016, p. 1101-1108.

Research output: Contribution to journalArticle

@article{664c040048ef4a3f82821df216e6ae11,
title = "The development, safety and efficacy of pacritinib for the treatment of myelofibrosis",
abstract = "Introduction: Dysregulation of janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has been described in myelofibrosis (MF). Currently, there is an unmet need for agents that have the benefit of JAK inhibition, yet also are safe and effective in patients with thrombocytopenia. Areas covered: We discuss the various preclinical and clinical studies describing pacritinib, a selective JAK2/FLT3 inhibitor. So far, it has shown promising results, without significant thrombocytopenia. A PubMed search, using keywords ‘pacritinib’, ‘SB 1518’ and ‘myelofibrosis’ was conducted. Published abstracts from recent national and international meetings were also reviewed for unpublished data. Expert commentary: Currently, pacritinib is on hold by Food and Drugs Administration. It would be imperative to understand if there is a treatment related toxicity that would limit its use. If a safe path is found for this agent, it could have a significant benefit in various settings, based on the data so far.",
keywords = "Anemia, JAK2 inhibitor, Myelofibrosis, Pacritinib, Thrombocytopenia",
author = "Tania Jain and Ruben Mesa",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/14737140.2016.1233061",
language = "English (US)",
volume = "16",
pages = "1101--1108",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - The development, safety and efficacy of pacritinib for the treatment of myelofibrosis

AU - Jain, Tania

AU - Mesa, Ruben

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: Dysregulation of janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has been described in myelofibrosis (MF). Currently, there is an unmet need for agents that have the benefit of JAK inhibition, yet also are safe and effective in patients with thrombocytopenia. Areas covered: We discuss the various preclinical and clinical studies describing pacritinib, a selective JAK2/FLT3 inhibitor. So far, it has shown promising results, without significant thrombocytopenia. A PubMed search, using keywords ‘pacritinib’, ‘SB 1518’ and ‘myelofibrosis’ was conducted. Published abstracts from recent national and international meetings were also reviewed for unpublished data. Expert commentary: Currently, pacritinib is on hold by Food and Drugs Administration. It would be imperative to understand if there is a treatment related toxicity that would limit its use. If a safe path is found for this agent, it could have a significant benefit in various settings, based on the data so far.

AB - Introduction: Dysregulation of janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has been described in myelofibrosis (MF). Currently, there is an unmet need for agents that have the benefit of JAK inhibition, yet also are safe and effective in patients with thrombocytopenia. Areas covered: We discuss the various preclinical and clinical studies describing pacritinib, a selective JAK2/FLT3 inhibitor. So far, it has shown promising results, without significant thrombocytopenia. A PubMed search, using keywords ‘pacritinib’, ‘SB 1518’ and ‘myelofibrosis’ was conducted. Published abstracts from recent national and international meetings were also reviewed for unpublished data. Expert commentary: Currently, pacritinib is on hold by Food and Drugs Administration. It would be imperative to understand if there is a treatment related toxicity that would limit its use. If a safe path is found for this agent, it could have a significant benefit in various settings, based on the data so far.

KW - Anemia

KW - JAK2 inhibitor

KW - Myelofibrosis

KW - Pacritinib

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84991666216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991666216&partnerID=8YFLogxK

U2 - 10.1080/14737140.2016.1233061

DO - 10.1080/14737140.2016.1233061

M3 - Article

VL - 16

SP - 1101

EP - 1108

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 11

ER -